Engchem Life Sciences and Korea Institute of Radiological & Medical Sciences to Jointly Develop Treatment for Radiation-Induced Dermatitis

Expanding Collaboration in Radiological Life Sciences

Building on Previous GI-ARS Joint Research Experience

Engchem Life Sciences announced on August 4 that it has signed a memorandum of understanding (MOU) for joint research collaboration with the Korea Institute of Radiological & Medical Sciences to develop a treatment for radiation-induced dermatitis.

Image of a treatment for radiation-induced dermatitis. Enzychem Lifesciences

The two institutions will review the feasibility of developing a treatment for radiation-induced dermatitis and will pursue joint research initiatives. Engchem Life Sciences will be responsible for establishing the development strategy, while the Korea Institute of Radiological & Medical Sciences will conduct efficacy studies, with both parties planning to gradually explore further collaborative development steps.

Radiation-induced dermatitis is a common side effect experienced by cancer patients undergoing radiation therapy, which can lead to delays or interruptions in treatment. Currently, care is focused on symptom relief using moisturizers and topical steroids, but there is a significant unmet medical need for new therapeutics in this area.

This collaboration expands the scope of research into the field of radiation therapy side effects, building on the cooperative relationship the two institutions have established through their previous joint research on gastrointestinal acute radiation syndrome (GI-ARS).

This content was produced with the assistance of AI translation services.